Linked Data API

Show Search Form

Search Results

767533
star this property registered interest false more like this
star this property date less than 2017-10-09more like thismore than 2017-10-09
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Nabiximols more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what medical evidence his Department has recently taken into account in its decision not to license nabiximols for use on the NHS. more like this
star this property tabling member constituency Richmond Park more like this
star this property tabling member printed
Zac Goldsmith remove filter
star this property uin 106691 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-10-12more like thismore than 2017-10-12
star this property answer text <p>Nabiximols (Sativex) is licensed in the United Kingdom for the treatment of moderate to severe spasticity in multiple sclerosis. The National Institute of Health and Care Excellence (NICE) did not recommended nabiximols in its 2014 clinical guidelines as it is not a cost-effective treatment.</p><p> </p><p>NICE develops authoritative, evidence-based guidance on best practice for the National Health Service. NICE operates with a high degree of independence from the Government and is responsible for the recommendations that it makes to the NHS. Its guidance is based on a thorough assessment of the available evidence and is developed through engagement with stakeholders.</p><p> </p><p>However, where there is an absence of final guidance recommendations from NICE, decisions on the funding of a licensed treatment on the NHS are taken by the relevant clinician and commissioner (such as NHS England or individual clinical commissioning groups) based on the individual needs of the patient.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
remove filter
star this property answering member
4067
unstar this property label Biography information for Steve Brine more like this
star this property tabling member
4062
unstar this property label Biography information for Zac Goldsmith more like this